Linda S. Ahn

1.3k total citations
25 papers, 785 citations indexed

About

Linda S. Ahn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Linda S. Ahn has authored 25 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Linda S. Ahn's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (8 papers) and Sarcoma Diagnosis and Treatment (6 papers). Linda S. Ahn is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (8 papers) and Sarcoma Diagnosis and Treatment (6 papers). Linda S. Ahn collaborates with scholars based in United States and Switzerland. Linda S. Ahn's co-authors include Robert G. Maki, Mary Louise Keohan, Cristina R. Antonescu, David R. D’Adamo, Samuel Singer, Angela Cioffi, Pamela R. Merola, Roberto García, Elizabeth G. Demicco and Murray F. Brennan and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Linda S. Ahn

24 papers receiving 772 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Linda S. Ahn United States 11 470 347 325 214 208 25 785
Ghadah Al Sannaa United States 12 333 0.7× 130 0.4× 239 0.7× 151 0.7× 110 0.5× 18 555
Alanna J. Church United States 15 346 0.7× 139 0.4× 199 0.6× 266 1.2× 166 0.8× 55 830
Munir R. Tanas United States 20 670 1.4× 343 1.0× 140 0.4× 329 1.5× 149 0.7× 43 1.2k
Yoshinao Oda Japan 14 320 0.7× 165 0.5× 117 0.4× 281 1.3× 135 0.6× 21 734
Jim Janinis Greece 12 266 0.6× 238 0.7× 89 0.3× 213 1.0× 138 0.7× 22 590
Gaetano Apice Italy 15 684 1.5× 202 0.6× 72 0.2× 556 2.6× 160 0.8× 40 1.0k
Amando Peydró-Olaya Spain 18 562 1.2× 233 0.7× 210 0.6× 175 0.8× 123 0.6× 37 757
Nicolas Macagno France 13 196 0.4× 158 0.5× 90 0.3× 231 1.1× 61 0.3× 65 679
Licciana Zanella Italy 14 595 1.3× 302 0.9× 67 0.2× 289 1.4× 67 0.3× 21 802
Lisa Glantz United States 9 328 0.7× 89 0.3× 157 0.5× 199 0.9× 106 0.5× 12 654

Countries citing papers authored by Linda S. Ahn

Since Specialization
Citations

This map shows the geographic impact of Linda S. Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda S. Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda S. Ahn more than expected).

Fields of papers citing papers by Linda S. Ahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda S. Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda S. Ahn. The network helps show where Linda S. Ahn may publish in the future.

Co-authorship network of co-authors of Linda S. Ahn

This figure shows the co-authorship network connecting the top 25 collaborators of Linda S. Ahn. A scholar is included among the top collaborators of Linda S. Ahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda S. Ahn. Linda S. Ahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Helena A., Monica F. Chen, Angela Bik‐Yu Hui, et al.. (2024). A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.. Journal of Clinical Oncology. 42(16_suppl). 8517–8517. 6 indexed citations
2.
Chen, Monica F., Àlvaro Quintanal-Villalonga, Jake J. Lee, et al.. (2024). Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.. Journal of Clinical Oncology. 42(16_suppl). 8565–8565. 5 indexed citations
3.
Elkrief, Arielle, Alex Makhnin, Linda S. Ahn, et al.. (2023). Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR -Mutant Lung Adenocarcinomas. Clinical Cancer Research. 29(8). 1423–1428. 1 indexed citations
4.
Paik, Paul K., Jia Luo, Ni Ai, et al.. (2022). Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nature Communications. 13(1). 6095–6095. 13 indexed citations
5.
Paik, Paul K., Pang‐Dian Fan, Besnik Qeriqi, et al.. (2022). Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228. Journal of Thoracic Oncology. 18(4). 516–526. 22 indexed citations
6.
Ahn, Linda S.. (2022). Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer. Clinical journal of oncology nursing. 26(5). 543–551. 3 indexed citations
7.
Luo, Jia, Alex Makhnin, Linda S. Ahn, et al.. (2021). Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precision Oncology. 5(5). 55–64. 10 indexed citations
8.
Arbour, Kathryn C., Eusebio Manchado, Matthew J. Bott, et al.. (2021). Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. JTO Clinical and Research Reports. 3(1). 100256–100256. 9 indexed citations
9.
Paik, Paul K., Rachel K. Kim, Linda S. Ahn, et al.. (2020). A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Clinical Cancer Research. 26(8). 1796–1802. 10 indexed citations
10.
Paik, Paul K., Linda S. Ahn, Andrew J. Plodkowski, Pang‐Dian Fan, & Charles M. Rudin. (2020). Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.. Journal of Clinical Oncology. 38(15_suppl). 9607–9607. 5 indexed citations
11.
Drilon, Alexander, Adam J. Schoenfeld, Kathryn C. Arbour, et al.. (2019). Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Molecular Case Studies. 5(2). a003665–a003665. 24 indexed citations
12.
Paik, Paul K., Linda S. Ahn, Michelle S. Ginsberg, et al.. (2018). P2.13-44 Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228. Journal of Thoracic Oncology. 13(10). S816–S816.
13.
Paik, Paul K., Linda S. Ahn, Andrew J. Plodkowski, et al.. (2018). A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed PD-L1 IHC low/unknown stage IV squamous cell lung cancers.. Journal of Clinical Oncology. 36(15_suppl). e21035–e21035. 1 indexed citations
14.
D’Adamo, David R., Mark A. Dickson, Mary Louise Keohan, et al.. (2018). A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. The Oncologist. 24(6). 857–863. 15 indexed citations
15.
Paik, Paul K., Besnik Qeriqi, Linda S. Ahn, et al.. (2018). Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.. Journal of Clinical Oncology. 36(15_suppl). 9098–9098. 2 indexed citations
16.
Ni, Ai, Linda S. Ahn, William D. Travis, et al.. (2017). Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung Cancer. 108. 205–211. 42 indexed citations
17.
Farid, Mohamad, Linda S. Ahn, Andrew S. Brohl, Angela Cioffi, & Robert G. Maki. (2014). Consumptive Coagulopathy in Angiosarcoma: A Recurrent Phenomenon?. Sarcoma. 2014. 1–7. 10 indexed citations
18.
Demicco, Elizabeth G., Roberto García, Linda S. Ahn, et al.. (2014). Malignant Peripheral Nerve Sheath Tumors. The Oncologist. 19(2). 193–201. 226 indexed citations
19.
Gounder, Mrinal M., Robert A. Lefkowitz, Mary Louise Keohan, et al.. (2011). Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis. Clinical Cancer Research. 17(12). 4082–4090. 177 indexed citations
20.
Camargo, Veridiana Pires de, Mary Louise Keohan, David R. D’Adamo, et al.. (2010). Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 116(9). 2258–2265. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ghadah Al Sannaa Breakdown of academic impact, for papers by Alanna J. Church Breakdown of academic impact, for papers by Munir R. Tanas Breakdown of academic impact, for papers by Yoshinao Oda Breakdown of academic impact, for papers by Jim Janinis Breakdown of academic impact, for papers by Gaetano Apice Breakdown of academic impact, for papers by Amando Peydró-Olaya Breakdown of academic impact, for papers by Nicolas Macagno Breakdown of academic impact, for papers by Licciana Zanella Breakdown of academic impact, for papers by Lisa Glantz
Rankless by CCL
2026